Arvind Tewari is currently Deputy Chief Executive Officer of M42 Bahrain, the country expansion of M42, one of the largest healthcare operators in the Middle East and Asia. He brings over 15 years of experience across strategy, operations, and finance in the global healthcare and life science space. 

He was previously Vice President at Atai Life Sciences, a neuropsychiatry biopharmaceutical, where he was responsible for building Atai’s digital function and was part of the senior leadership team that listed Atai on the Nasdaq. Prior to Atai, he was Chief Operating Officer of OxfordVR, an Oxford University spin-out focused on treating Schizophrenia in the UK’s NHS. He is currently a Non-Executive Director of the Royal Trinity Palliative Care Centre in London.

Arvind began his career in European private equity and M&A at Rothschild and holds a degree in Molecular and Cellular Biochemistry from the University of Oxford.